Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica.
Rheum Dis Clin North Am
; 50(2): 255-267, 2024 May.
Article
em En
| MEDLINE
| ID: mdl-38670724
ABSTRACT
Polymyalgia rheumatica (PMR) immune-related adverse events (ICI-PMRs) represent a novel, distinct entity, despite many clinical, laboratory, and imaging similarities to classical PMR. Important questions remain in differentiating ICI-PMR from classical PMR, as well as other immune-related adverse events and PMR mimics. Despite this, ICI-PMR currently takes treatment cues from classical PMR, albeit with considerations relevant to cancer immunotherapy. Comparisons between ICI-PMR and classical PMR may provide further bidirectional insights, especially given that important questions remain unanswered about both diseases. The cause of classical PMR remains poorly understood, and ICI-PMR may represent a model of induced PMR, with important therapeutic implications.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Polimialgia Reumática
/
Inibidores de Checkpoint Imunológico
Limite:
Humans
Idioma:
En
Revista:
Rheum Dis Clin North Am
Ano de publicação:
2024
Tipo de documento:
Article